beta

ALBO

Albireo Pharma, Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Albireo Pharma, Inc. engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. It pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Market Cap: 389 Million

Primary Exchange: NASDAQ

Website: http://www.albireopharma.com

Shares Outstanding: 15 Million

Float: 14 Million

Dividend: (%)

Beta: 1.35375909657652

Sector: Health Technology

Industry: Pharmaceuticals: Other

Ethical Flags

Longest drawdown: 2270 trading days

From: 2013-08-02 To: 2020-07-02

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
2016-11-04 30.0 1.0 30.0
Data provided by IEX Cloud